SCHEMBL20697268

SCHEMBL20697268

CCOC(=O)c1cnn2c(NCCCN3CCOCC3)cc(Cl)nc12

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.54
KMT2A Q03164 5/20 0.54
KDM4E B2RXH2 3/20 0.54
HSD17B10 Q99714 3/20 0.54
NPC1 O15118 2/20 0.54
ALDH1A1 P00352 2/20 0.54
HPGD P15428 2/20 0.54
RAB9A P51151 2/20 0.54
USP2 O75604 1/20 0.54
MAPT P10636 1/20 0.54
HTT P42858 1/20 0.54
ATM Q13315 1/20 0.53
RAD52 P43351 2/20 0.53
UHRF1 Q96T88 1/20 0.53
MAPK1 P28482 1/20 0.52
RXFP1 Q9HBX9 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
POLB P06746 1/20 0.51
TYK2 P29597 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20696781 0.94 RXFP1 (0.52) MEN1KMT2AKDM4EHSD17B10NPC1
SCHEMBL17182911 0.80 KDM4E (0.57) MEN1KMT2AKDM4EHSD17B10NPC1
SCHEMBL25162622 0.78 ATM (0.62) MEN1KMT2AKDM4EHSD17B10ATM
SCHEMBL30366018 0.78 ATM (0.62) MEN1KMT2AKDM4EHSD17B10ATM
SCHEMBL20697263 0.78 POLB (0.43) MEN1KMT2AKDM4EHSD17B10ALDH1A1
SCHEMBL20689018 0.77 KDM4E (0.52) MEN1KMT2AKDM4EHSD17B10NPC1
SCHEMBL34462300 0.76 ATM (0.62) MEN1KMT2AKDM4EHSD17B10ALDH1A1
SCHEMBL20689052 0.75 POLB (0.41) MEN1KMT2AKDM4EHSD17B10NPC1
SCHEMBL20697186 0.75 KDM4E (0.53) KDM4EHSD17B10NPC1ALDH1A1HPGD
SCHEMBL31245710 0.74 KDM4E (0.49) MEN1KMT2AKDM4EHSD17B10NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230056447-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-02-23 US disclosed
US-11046698-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2021-06-29 US disclosed
US-10577373-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2020-03-03 US disclosed
US-10570145-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2020-02-25 US disclosed
US-10562906-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2020-02-18 US disclosed
US-10562907-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2020-02-18 US disclosed
US-20190256519-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-22 US disclosed
US-20190248797-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-15 US disclosed
US-20190241576-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-08 US disclosed
US-20190241575-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-08 US disclosed
US-20190241577-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-08 US disclosed
US-20190031664-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190248797-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 MEN1 2491/4885KMT2A 206/4885KDM4E 391/4885
US-11046698-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 MEN1 2491/4885KMT2A 206/4885KDM4E 391/4885
US-20190256519-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 MEN1 2491/4885KMT2A 206/4885KDM4E 391/4885
US-20190031664-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 MEN1 2491/4885KMT2A 206/4885KDM4E 391/4885
US-20190241577-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 MEN1 2491/4885KMT2A 206/4885KDM4E 391/4885
US-10562906-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 MEN1 2491/4885KMT2A 206/4885KDM4E 391/4885
US-20190241576-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 MEN1 2491/4885KMT2A 206/4885KDM4E 391/4885
US-20190241575-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 MEN1 2491/4885KMT2A 206/4885KDM4E 391/4885
US-20230056447-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 MEN1 2491/4885KMT2A 206/4885KDM4E 391/4885
US-10570145-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 MEN1 2491/4885KMT2A 206/4885KDM4E 391/4885
US-10577373-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 MEN1 2491/4885KMT2A 206/4885KDM4E 391/4885
US-10562907-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 MEN1 2491/4885KMT2A 206/4885KDM4E 391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.